Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-387 vs D484 in Healthy Adults
NCT03646799Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of D484 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration (Cmax) of Dapagliflozin at 48 hours, Maximum Plasma Concentration (Cmax) of Metformin at 48 hours and 2 more. Status: unknown.
02
Drugs
D484
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03646799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646799.